We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
-1.26%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$194M
AUM Growth
-$37.2M
Cap. Flow
-$3.74M
Cap. Flow %
-1.92%
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ARTV
Artiva Biotherapeutics
ARTV
+$17.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$14.8M
2
ELEV
Elevation Oncology
ELEV
+$6.57M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$79.4M 40.88%
4,289,304
– –
ALMS
2
Alumis Inc
ALMS
$3.57B
$30.2M 15.53%
2,826,048
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$24.6M 12.65%
614,594
-420,802
-41% -$14.8M
ARTV
4
Artiva Biotherapeutics
ARTV
$487M
$23.5M 12.08%
+1,519,971
New +$17.6M
SLRN
5
DELISTED
ACELYRIN
SLRN
$19M 9.77%
3,852,470
– –
ALXO icon
6
ALX Oncology
ALXO
$273M
$17.7M 9.08%
9,699,925
– –
ELEV
7
DELISTED
Elevation Oncology
ELEV
– –
-2,434,255
Closed -$6.57M

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q3 2024 Portfolio in Review

As of Q3 2024, venBio Partners held 7 positions worth $194M, down 16% from $232M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners's Q3 2024 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was Artiva Biotherapeutics: 1,519,971 shares worth $23.5M. The largest sale was Harmony Biosciences, an estimated $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's largest Q3 2024 buy was Artiva Biotherapeutics: 1,519,971 shares worth $23.5M.
  • venBio Partners's biggest Q3 2024 reduction was Harmony Biosciences, cutting an estimated $14.8M.
  • venBio Partners fully exited Elevation Oncology in Q3 2024, selling an estimated $6.57M.
  • venBio Partners's ten largest holdings make up 100% of its $194M portfolio in Q3 2024.
  • venBio Partners opened 1 new position and closed 1 in Q3 2024.
  • venBio Partners's portfolio value fell 16% quarter-over-quarter to $194M.

Based on venBio Partners's 13F filing for Q3 2024, filed 14 Nov 2024.